Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2026
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 29, 2026
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.
Journal: The New England journal of medicine
Published: May 29, 2026
Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.
Journal: American journal of hematology
Published: May 04, 2026
Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 16, 2026
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients.
Journal: American journal of hematology
Published: January 20, 2026
Endless possibilities and how to exploit them? What is the optimal treatment sequence?
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Treatment response assessment using whole body diffusion weighted-magnetic resonance imaging in myeloma: a retrospective cohort study.
Journal: Leukemia & lymphoma
Published: November 11, 2025
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era.
Journal: HemaSphere
Published: July 31, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Journal: Blood cancer journal
Published: July 01, 2025
Last Updated: 09/26/2026